Payment overview · 2025
General Payments
$439.18
17 reported records · 8 companies
Healthcare provider profile · identity verified
Raymond Nmn Broughton, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAYOU LA BATRE, AL · NPI 1790734788
Verified facts
What the public records show
CMS Open Payments records show Raymond Nmn Broughton, MD received $439.18 in general payments during 2025 across 17 reported records.
Neurocrine BioSciences, Inc. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $114.57 | 26.1% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $86.10 | 19.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $61.92 | 14.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $60.78 | 13.8% | 2 | 2025 |
| Procept Biorobotics Corporation | Unresolved — no canonical attribution shown | $50.92 | 11.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.01 | 5.5% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $23.63 | 5.4% | 1 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $17.25 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.18 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $114.57 | 5 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $86.10 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $60.78 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $59.30 | 2 | 2025 |
Source payment records
|
|||||
| AQUABEAM ROBOTIC SYSTEM Normalized: aquabeam robotic system |
Device | Procept Biorobotics Corporation | $50.92 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $32.62 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.30 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| INTRAROSA Normalized: intrarosa |
Drug | MILLICENT US INC | $17.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
101 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 817 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 158 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 445 | 97 |
| Simvastatin | Simvastatin | 381 | 104 |
| Potassium Chloride | Potassium Chloride | 321 | 85 |
| Metformin Hcl | Metformin Hcl | 310 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 297 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 282 | 66 |
| Furosemide | Furosemide | 279 | 88 |
| Lisinopril | Lisinopril | 275 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 84 |
| Ibuprofen | Ibuprofen | 269 | 88 |
| Carvedilol | Carvedilol | 232 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 67 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 190 | 52 |
| Omeprazole | Omeprazole | 181 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 170 | 51 |
| Pregabalin | Pregabalin | 158 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 156 | 23 |
| Tramadol Hcl | Tramadol Hcl | 154 | 28 |
| Cefdinir | Cefdinir | 146 | 121 |
| Glipizide | Glipizide | 142 | 37 |
| Clonazepam | Clonazepam | 140 | 23 |
| Meclizine Hcl | Meclizine Hcl | 126 | 36 |
| Farxiga | Dapagliflozin Propanediol | 122 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 38 |
| Trazodone Hcl | Trazodone Hcl | 117 | 41 |
| Alendronate Sodium | Alendronate Sodium | 115 | 32 |
| Linzess | Linaclotide | 101 | 44 |
| Ozempic | Semaglutide | 98 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 26 |
| Meloxicam | Meloxicam | 93 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 23 |
| Lorazepam | Lorazepam | 81 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 78 | 26 |
| Baclofen | Baclofen | 77 | 26 |
| Prednisone | Prednisone | 77 | 60 |
| Eliquis | Apixaban | 68 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 19 |
| Glipizide Er | Glipizide | 63 | 23 |
| Mounjaro | Tirzepatide | 63 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 63 | 21 |
| Colchicine | Colchicine | 60 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 19 |
| Allopurinol | Allopurinol | 57 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 20 |
| Buspirone Hcl | Buspirone Hcl | 51 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 16 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 46 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 12 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 39 |
| Losartan Potassium | Losartan Potassium | 44 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Ezetimibe | Ezetimibe | 43 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 36 |
| Fenofibrate | Fenofibrate | 41 | 11 |
| Irbesartan | Irbesartan | 41 | 14 |
| Xarelto | Rivaroxaban | 41 | 11 |
| Famotidine | Famotidine | 40 | 13 |
| Celecoxib | Celecoxib | 39 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 14 |
| Mirtazapine | Mirtazapine | 38 | 14 |
| Mometasone Furoate | Mometasone Furoate | 37 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 23 |
| Dutasteride | Dutasteride | 35 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Felodipine Er | Felodipine | 30 | suppressed |
| Ranolazine Er | Ranolazine | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | 12 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 17 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Ibu | Ibuprofen | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $439.18 · 17 records | Neurocrine BioSciences, Inc. | ABILIFY MAINTENA, AQUABEAM ROBOTIC SYSTEM, ARISTADA, CAPLYTA, Doc Band, FEMLYV, INGREZZA, INTRAROSA, LYBALVI, MAVYRET, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error